Inhibrx Biosciences, Inc. (INBX): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:08 ET
- Event date
- 2026-11-13
- Accession no.
- 0002007919-26-000057
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Inhibrx reports third-quarter 2026 results and clinical program updates
Inhibrx reported a third-quarter 2026 net loss of $38.7 million, compared to $35.3 million for the third quarter of 2025, and $2.0 million in license revenue from Pfizer, Inc. The company also disclosed ongoing clinical enrollment and expected mid-2027 results for ordastobart studies in head and neck cancer and non-small cell lung cancer.
- Third-quarter 2026 net loss was $38.7 million, or $2.46 per share, basic and diluted.
- Cash and cash equivalents totaled $199.5 million as of September 30, 2026.
- Third-quarter 2026 revenue was $2.0 million under a non-exclusive patent license agreement with Pfizer, Inc.
- Research and development expenses were $26.0 million, compared to $28.5 million for the third quarter of 2025.
earningsproduct
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | inhibrx-20261113.htm |
| EX-99.1 | EX-99.1 | exhibit99109302026.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.